Gynecologic Cancers | Clinical

Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer

October 20, 2020

Several late-phase results were shared during the European Society of Medical Oncology Virtual Congress in gynecologic malignancies, but the data presented generated excitement about the number of novel options for patients after initial treatment.

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 21, 2020

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial

September 21, 2020

In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.

Tisotumab Vedotin Shows Promise in Recurrent/Metastatic Cervical Cancer

September 21, 2020

In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.

Durable Antitumor Activity Achieved With Dostarlimab in Mismatch Repair Proficient/dMMR Endometrial Cancer

September 20, 2020

In the phase 1 GARNET trial, durable antitumor activity was observed with dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer. The disease control rate was promising and the safety profile of the agent was tolerable, according to results presented during the 2020 European Society of Medical Oncology Virtual Congress.

Activity Observed With Balstilimab With or Without Zalifrelimab for Cervical Cancer

September 19, 2020

In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.